Vishal Navani

10PUBLICATIONS
22CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPharmaceutical delivery technologiesPredictive and prognostic markersTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Sep 24, 2026
Toxicity, Dose Intensity, and Clinical Outcomes with First-Line Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Real-World Study.

|Mar 03, 2025
Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study.

Amin H Nassar, Sarah Abou Alaiwi, Talal El Zarif

|Jul 26, 2024
What Is Ailing Oncology Clinical Trials? Can We Fix Them?

Abhenil Mittal, Sara Moore, Vishal Navani

|May 24, 2024
New Anticancer Drugs: Reliably Assessing "Value" While Addressing High Prices.

David J Stewart, John-Peter Bradford, Sandeep Sehdev

|May 24, 2024
Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for EGFR Mutation-Positive Patients Treated with First-Line Osimertinib.

Amanda Jane Williams Gibson, Michelle Liane Dean, Ishjot Litt

|Apr 03, 2023
Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors.

Igor Stukalin, Vishal Navani, Mehul Gupta

Pageof 2

Frequent Collaborators

3 joint publications

Di Maria Jiang

2 joint publications

Moira C Graves

2 joint publications

Nikola A Bowden

2 joint publications

David J Stewart